Comparison of Intratympanic, Systemic, and Combined Steroid Therapies for Sudden Sensorineural Hearing Loss in Patients with Diabetes Mellitus
2
조회
0
다운로드
2
인용
0
참고문헌
초록
Background and Objectives We investigated whether the intratympanic steroid injectionsmight be an effective initial treatment for sudden sensorineural hearing loss (SSNHL) in patientswith diabetes mellitus (DM). Subjects and Method We assessed a total of 167 patients with DM and SSNHL who visiteda tertiary referral otolaryngology department between January 2010 and April 2018. Fortytwopatients with DM and SSNHL received intratympanic steroid injections; 48 patients withDM and SSNHL received systemic steroid treatment; and 77 patients with DM and SSNHLreceived a combination of systemic and intratympanic treatment. Initial and post treatmenthearing levels and fasting blood sugar (FBS) were assessed, and correlations between hearinggain and the duration of DM, HbA1c, FBS were investigated. Results After steroid treatment, hearing levels were 38.87±25.35 dB in the intratympanicinjection group, 41.09±28.49 dB in the systemic steroid treatment group, and 47.81±27.12 dBin the combined treatment group. Final hearing levels and hearing gain in the three groups didnot differ significantly. FBS after treatment in the systemic steroid treatment and combinedsteroid treatment group worsened relative to the intratympanic injection group (202.00±9.40mg/dL to 326.63±7.85 mg/dL). FBS, duration of DM, and HbA1c levels did not affect the hearinggain in patients with DM and SSNHL. Conclusion Intratympanic steroid injections are comparable to the systemic steroid treatmentmodality for SSNHL in patients with DM. Thus, intratympanic steroid injections mayserve as an effective initial treatment modality for SSNHL in patients with DM.
Abstract
Background and Objectives We investigated whether the intratympanic steroid injectionsmight be an effective initial treatment for sudden sensorineural hearing loss (SSNHL) in patientswith diabetes mellitus (DM). Subjects and Method We assessed a total of 167 patients with DM and SSNHL who visiteda tertiary referral otolaryngology department between January 2010 and April 2018. Fortytwopatients with DM and SSNHL received intratympanic steroid injections; 48 patients withDM and SSNHL received systemic steroid treatment; and 77 patients with DM and SSNHLreceived a combination of systemic and intratympanic treatment. Initial and post treatmenthearing levels and fasting blood sugar (FBS) were assessed, and correlations between hearinggain and the duration of DM, HbA1c, FBS were investigated. Results After steroid treatment, hearing levels were 38.87±25.35 dB in the intratympanicinjection group, 41.09±28.49 dB in the systemic steroid treatment group, and 47.81±27.12 dBin the combined treatment group. Final hearing levels and hearing gain in the three groups didnot differ significantly. FBS after treatment in the systemic steroid treatment and combinedsteroid treatment group worsened relative to the intratympanic injection group (202.00±9.40mg/dL to 326.63±7.85 mg/dL). FBS, duration of DM, and HbA1c levels did not affect the hearinggain in patients with DM and SSNHL. Conclusion Intratympanic steroid injections are comparable to the systemic steroid treatmentmodality for SSNHL in patients with DM. Thus, intratympanic steroid injections mayserve as an effective initial treatment modality for SSNHL in patients with DM.
참고문헌 (23)
- Seggas I, "Intratympanic steroid therapy for sudden hearing loss : a review of the literature", Otol Neurotol, 32(1), pp.29~35 (2011)
- Zhao D, "A comparison of effects of systemic and intratympanic steroid therapies for sudden sensorineural hearing loss : A meta-analysis", J Otol, 11(1), pp.18~23 (2016)
- Rauch SD, "Clinical practice. Idiopathic sudden sensorineural hearing loss", N Engl J Med, 359(8), pp.833~840 (2008)
- Wilson WR, "The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double-blind clinical study", Arch Otolaryngol, 106(12), pp.772~776 (1980)
- Shaikh JA, "Does addition of antiviral medication to high-dose corticosteroid therapy improve hearing recovery following idiopathic sudden sensorineural hearing loss?", Laryngoscope, 121(11), pp.2280~2281 (2011)
- Klemm E, "Hemodilution therapy with hydroxyethyl starch solution (130", 0.4) in unilateral idiopathic sudden sensorineural hearing loss: A dosefinding, double-blind, placebo-controlled, international multicenter trial with 210 patients, 2007, pp.28(2), 157~170
- Ogawa K, "Effect of prostaglandin E1 on idiopathic sudden sensorineural hearing loss : A double-blinded clinical study", Otol Neurotol, 23(5), pp.665~668 (2002)
- Liu SC, "Comparison of therapeutic results in sudden sensorineural hearing loss with", without additional hyperbaric oxygen therapy : A retrospective review of 465 audiologically controlled cases, 2011, pp.36(2), 121~128
- Shikowitz MJ, "Sudden sensorineural hearing loss", Med Clin North Am, 75(6), pp.1239~1250 (1991)
- Jorgensen MB, "The inner ear in diabetes mellitus. Histological studies", Arch Otolaryngol, 74, pp.373~381 (1961)
- Han CS, "Clinical efficacy of initial intratympanic steroid treatment on sudden sensorineural hearing loss with diabetes", Otolaryngol Head Neck Surg, 141(5), pp.572~578 (2009)
- Maksoud A, "Intratympanic dexamethasone injection in Meniere’s disease", Egypt J Otolaryngol, 31(2), pp.128~134 (2015)
- Siegel LG, "The treatment of idiopathic sudden sensorineural hearing loss", Otolaryngol Clin North Am, 8(2), pp.467~473 (1975)
- Hobson CE, "Primary treatment of idiopathic sudden sensorineural hearing loss with intratympanic dexamethasone", Curr Opin Otolaryngol Head Neck Surg, 24(5), pp.407~412 (2016)
- Kakehata S, "Comparison of intratympanic and intravenous dexamethasone treatment on sudden sensorineural hearing loss with diabetes", Otol Neurotol, 27(5), pp.604~608 (2006)
- Silverstein H, "Intratympanic steroid treatment of inner ear disease and tinnitus(preliminary report)", Ear Nose Throat J, 75(8), pp.468~471 (1996)
- Ho HG, "Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment", Laryngoscope, 114(7), pp.1184~1189 (2004)
- Trune DR, "Glucocorticoid impact on cochlear function and systemic side effects in autoimmune C3.MRL-Faslpr and normal C3H", HeJ mice, 2007, pp.226(1-2), 209~217
- Skubitz KM, "Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro", J Clin Invest, 68(1), pp.13~20 (1981)
- Trune DR, "Mineralocorticoid receptor mediates glucocorticoid treatment effects in the autoimmune mouse ear", Hear Res, 212(1-2), pp.22~32 (2006)
- Ermutlu G, "Sudden hearing loss : An effectivity comparison of intratympanic and systemic steroid treatments", Eur Arch Otorhinolaryngol, 274(10), pp.3585~3591 (2017)
- Rust KR, "Inner ear damage secondary to diabetes mellitus. II. Changes in aging SHR", N-cp rats, 1992, pp.118(4), 397~400
- Karabulut H, "Evaluation of outer hair cell function and medial olivocochlear efferent system in patients with type II diabetes mellitus", Turk J Med Sci, 44(1), pp.150~156 (2014)